Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

OBJECTIVES: There are currently few data on the long‐term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. METHODS: The EuroSIDA cohort was divided into three groups: those starting RAL‐based comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozzi‐Lepri, A, Zangerle, R, Machala, L, Zilmer, K, Ristola, M, Pradier, C, Kirk, O, Sambatakou, H, Fätkenheuer, G, Yust, I, Schmid, P, Gottfredsson, M, Khromova, I, Jilich, D, Flisiak, R, Smidt, J, Rozentale, B, Radoi, R, Losso, MH, Lundgren, JD, Mocroft, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813233/
https://www.ncbi.nlm.nih.gov/pubmed/28984429
http://dx.doi.org/10.1111/hiv.12557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813233/
https://www.ncbi.nlm.nih.gov/pubmed/28984429
http://dx.doi.org/10.1111/hiv.12557

Ejemplares similares